Retatrutide vs CagriSema: Comparing 2026's Most-Watched Weight Loss Combos
The incretin therapy landscape is evolving at breakneck speed. While semaglutide and tirzepatide reshaped obesity treatment over the past few years, the next generation of multi-receptor agonists and combination therapies promises even greater efficacy. Two candidates stand at the forefront of this next wave: retatrutide, Eli Lilly's triple hormone receptor agonist, and CagriSema, Novo Nordisk's fixed-dose combination of cagrilintide and semaglutide.
Both are in Phase 3 clinical trials with pivotal data expected in 2025–2026. Understanding how these two approaches differ — mechanistically, clinically, and practically — is essential for anyone tracking the future of metabolic peptide research.
How Retatrutide Works: The Triple Agonist Approach
Retatrutide (LY3437943) is a single-molecule agonist that simultaneously activates three receptors: GLP-1, GIP, and glucagon receptors. This triple agonist mechanism builds on the dual GLP-1/GIP agonism pioneered by tirzepatide but adds glucagon receptor activation as a third pillar.
GLP-1 receptor agonism drives appetite suppression and improved glycemic control. GIP receptor agonism appears to enhance insulin sensitivity and may contribute to fat metabolism, though its role remains under active investigation. The addition of glucagon receptor agonism is what makes retatrutide truly novel — glucagon increases energy expenditure, promotes hepatic lipid oxidation, and may directly reduce liver fat content.
In the Phase 2 trial published by Jastreboff et al., 2023 in The New England Journal of Medicine, retatrutide demonstrated unprecedented weight loss in participants with obesity. At the highest dose (12 mg), participants achieved a mean weight reduction of 24.2% at 48 weeks — a figure that surpassed anything previously reported for a single anti-obesity agent in a controlled trial.
Retatrutide is currently being evaluated in the Phase 3 TRIUMPH trial program, which includes studies in obesity (NCT05929066), type 2 diabetes, and metabolic dysfunction-associated steatohepatitis (MASH).
How CagriSema Works: The Combination Strategy
CagriSema takes a fundamentally different design philosophy. Rather than engineering a single molecule to hit multiple targets, Novo Nordisk combines two distinct peptides — cagrilintide (a long-acting amylin analog) and semaglutide (a GLP-1 receptor agonist) — into a single subcutaneous injection.
Amylin is a pancreatic hormone co-secreted with insulin that promotes satiety, slows gastric emptying, and suppresses postprandial glucagon secretion. Cagrilintide is an acylated, long-acting analog of amylin designed for once-weekly dosing. By pairing it with semaglutide, CagriSema targets two complementary satiety pathways that converge on distinct brain regions involved in appetite regulation.
The Phase 2 data published by Frias et al., 202301945-3) in The Lancet showed that CagriSema produced 15.6% mean weight loss at 32 weeks in adults with overweight or obesity without diabetes. Notably, the combination outperformed each component given alone — semaglutide 2.4 mg achieved 5.1% and cagrilintide 2.4 mg achieved 8.1% over the same period — suggesting genuine mechanistic synergy.
The Phase 3 REDEFINE program is extensive, encompassing trials in obesity (NCT05567796), type 2 diabetes (NCT05394519), and heart failure with preserved ejection fraction.
Head-to-Head Efficacy: What the Data Suggest So Far
Direct comparison between retatrutide and CagriSema is complicated by differences in trial duration, populations, and dosing. However, the available Phase 2 data offer a useful starting framework:
The CagriSema trial was shorter at 32 weeks, meaning the weight loss trajectory likely had not plateaued. Extrapolating from the curves, many researchers expect CagriSema's Phase 3 results to land in the 20–25% range at longer endpoints. Retatrutide's 48-week data similarly may not reflect the full plateau, and the TRIUMPH trials will clarify where final efficacy settles.
Beyond the Scale: Metabolic and Organ-Specific Effects
Weight loss alone doesn't capture the full therapeutic picture. Both candidates appear to offer metabolic benefits that extend well beyond adiposity reduction.
Retatrutide and liver fat: The glucagon receptor component gives retatrutide a potential edge in hepatic steatosis. Phase 2 sub-study data presented at EASL 2023 showed dramatic reductions in liver fat, with some participants achieving near-complete normalization. A dedicated MASH trial (NCT05936151) is underway, positioning retatrutide as a potential dual obesity-MASH therapy.
CagriSema and cardiovascular outcomes: Novo Nordisk can leverage the established cardiovascular benefit of semaglutide, demonstrated in the SELECT trial (Lincoff et al., 2023), which showed a 20% relative risk reduction in major adverse cardiovascular events. Whether cagrilintide adds further cardiovascular benefit is unknown, but the amylin pathway's effects on postprandial metabolism and glucagon suppression could theoretically contribute.
Safety and Tolerability Profiles
Both therapies share the class-typical gastrointestinal side effects common to incretin-based drugs — nausea, vomiting, diarrhea, and constipation. These are generally mild to moderate and tend to diminish with dose escalation.
Key safety observations from Phase 2 data include:
Long-term safety data for both candidates remain limited. Phase 3 trials with larger populations and longer durations will be critical for identifying rare adverse events and establishing the true risk-benefit ratio.
Practical and Commercial Considerations
From a practical standpoint, both therapies are administered as once-weekly subcutaneous injections, maintaining the convenience standard set by semaglutide and tirzepatide.
CagriSema has a potential manufacturing and regulatory advantage: it combines two well-characterized molecules, one of which (semaglutide) is already extensively approved. Retatrutide, as a novel single molecule, may face a higher regulatory evidence bar but offers the simplicity of a single active ingredient.
The competitive dynamics are also worth noting. Eli Lilly and Novo Nordisk are in a well-documented race to dominate the metabolic disease space. The sequencing of Phase 3 readouts and regulatory submissions in 2025–2026 could determine market positioning for years to come. Preliminary Phase 3 data from the REDEFINE 1 trial reportedly showed CagriSema achieving approximately 22.7% weight loss at 68 weeks (Novo Nordisk press release, 2024), confirming competitive efficacy.
Open Questions for the Field
Several important uncertainties remain as we await final Phase 3 results: